Bio-Path Holdings Announces Rescheduled Date and Time of Full Year 2016 Financial Results on March 15, 2017 BPTH_Earnings Announce_Rescheduled
Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board BPTH_Craig_Hooper_SAB_Release20170221
Bio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference BPTH_to_Present_at_BIO_CEO_Conf_20170214
Bio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual Meeting bpth-ash_poster_final_20161201
BIO-PATH HOLDINGS TO ANNOUNCE THIRD QUARTER 2016 FINANCIAL RESULTS ON NOVEMBER 10, 2016 bpth_earnings_announcement_3q16
Bio-Path Announces Orphan Drug Designation in the European Union for BP1001 for the Treatment of Acute Myeloid Leukemia bpth_eu_orphan_drug_20161103
